Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response
Purpose The aim of this study was to evaluate the long-term clinical outcomes of papillary thyroid carcinoma (PTC) patients exhibiting biochemical incomplete response (BIR) to initial therapy. Methods We evaluated 102 patients with PTC showing a BIR during the first 12–24 months after total thyroide...
Saved in:
Published in | Endocrine Vol. 67; no. 3; pp. 623 - 629 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
01.03.2020
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose
The aim of this study was to evaluate the long-term clinical outcomes of papillary thyroid carcinoma (PTC) patients exhibiting biochemical incomplete response (BIR) to initial therapy.
Methods
We evaluated 102 patients with PTC showing a BIR during the first 12–24 months after total thyroidectomy and radioactive iodine therapy. Patients were divided into three groups according to changes in stimulated thyroglobulin (Tg) and anti-Tg antibody (TgAb) levels: the increasing TgAb group (
n
= 19, 18.6%), the decreasing Tg group (
n
= 58, 56.9%), and the increasing Tg group (
n
= 25, 24.5%).
Results
With a median follow-up of 12 years, 43 (42%) patients had structural persistent disease as follows: 36 (84%) at regional sites and 7 (16%) at distant sites. The rate of structural persistent disease was significantly different between groups, with 21%, 41%, and 60% in the increasing TgAb, decreasing Tg, and increasing Tg groups, respectively (
P
= 0.012). Among patients without structural persistent disease, only 19 (18.6%) showed no evidence of disease and 40 (39.2%) were of a biochemical persistent status at the time of final follow-up. Increasing Tg after initial therapy was a significant risk factor for structural persistent disease in patients with BIR (HR, 4.16; 95% confidence interval (CI): 1.38
–
12.54,
P
= 0.011).
Conclusions
PTC patients with BIR showed a high rate of structural persistent disease and Tg change after initial therapy is the most important prognostic factor for determining clinical outcomes of these patients. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1355-008X 1559-0100 |
DOI: | 10.1007/s12020-019-02142-1 |